A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Table 1

The baseline characteristics of the two groups before and after PSM analysis.

Variables	TTP									OS
	Univariable analysis			Multivariable analysis			Univariable analysis			Multivariable analysis
	HR	95% CI	value	HR	95% CI	value	HR	95%CI	value	HR	95% CI	value
Age (years)	1.003	0.984, 1.023	0.744				1.006	0.984, 1.029	0.602
Albumin (g/L)	0.972	0.933, 1.013	0.183				0.976	0.935, 1.020	0.281
Bilirubin (umol/L)	1.019	0.994, 1.045	0.142				1.028	1.003, 1.053	0.026	1.019	0.985, 1.054	0.285
Maximal tumor size (cm)	1.169	1.097, 1.246	<0.001	1.170	1.097, 1.247	<0.001	1.284	1.196, 1.378	<0.001	1.293	1.203, 1.391	<0.001
Neutrophil-to-lymphocyte ratio	1.099	1.042, 1.160	<0.001	1.098	1.040, 1.159	0.001	1.084	1.026, 1.146	0.004	1.084	1.023, 1.150	0.007
Gender
Male	1						1	1
Female	1.072	0.609, 1.886	0.810				1.536	0.849, 2.779	0.156
HBV
Yes	1						1
No	0.624	0.324, 1.205	0.160				0.635	0.293, 1.376	0.250
Type of PVTT
I	1						1
II	1.260	0.821, 1.934	0.289				1.211	0.762, 1.926	0.417
III	1.188	0.596, 2.369	0.624				0.756	0.342, 1.668	0.488
Extrahepatic metastases
Yes	1						1
No	0.931	0.626, 1.384	0.724				1.002	0.653, 1.539	0.992
AFP (ng/L)
>400	1						1
≤400	0.777	0.527, 1.147	0.205				0.827	0.546, 1.252	0.369
Child–Pugh
A	1						1			1
B	1.403	0.858, 2.294	0.177				1.899	1.148, 3.142	0.013	1.565	0.753, 3.255	0.230
ECOG
1	1						1
2	1.268	0.658, 2.444	0.479				0.846	0.409, 1.751	0.652
Treatment
TACE + apatinib	1			1			1			1
TACE alone	2.245	1.497, 3.365	<0.001	2.117	1.391, 3.221	<0.001	2.358	1.531, 3.632	0.001	2.256	1.428, 3.565	<0.001

PSM, propensity score matching; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; AFP, A-fetoprotein; TACE, transarterial chemoembolization; PVTT, portal vein tumor thrombus.